Skip to main content
. 2015 Oct 15;6(35):37028–37042. doi: 10.18632/oncotarget.5939

Table 2. Correlations between RPL15 expression and clinicopathologic features in Renji cohort 2 patients with pancreatic ductal adenocarcinoma (PDAC).

Expression of RPL15
Clinicopathological feature Total 205 Low (n=103, 50.2%) High (n=102, 49.8%) P value (χ2 test)
Age(years)
 <65 97 48 (49.5) 49 (50.5) 0.837
 ≥65 108 55 (50.9) 53 (49.1)
Gender
 Male 117 60 (51.3) 57 (48.7) 0.732
 Female 88 43 (48.9) 45 (51.1)
Tumor location
 Head 139 71 (51.1) 68 (48.9) 0.729
 Body/tail 66 32 (48.5) 34 (51.5)
TNM stage(AJCC)
 Stage I 38 11 (28.9) 27 (71.1) 0.033
 Stage II 132 71 (53.8) 61 (46.2)
 Stage III 21 13 (61.9) 8 (38.1)
 Stage IV 14 7 (50.0) 7 (50.0)
Tumor size
 ≤2cm 27 12 (44.4) 15(55.6) 0.518
 >2cm 178 91 (51.1) 87 (48.9)
T classificattion
 T1,2 42 15(35.7) 27 (64.3) 0.035
 T3,4 163 88 (54.0) 75(46.0)
Lymph node metastasis
 Absent 136 63 (46.3) 73 (53.7) 0.115
 Present 69 40 (58.0) 29 (42.0)
Distant metastasis
 Absent 191 96 (50.3) 95 (49.7) 0.985
 Present 14 7 (50.0) 7 (50.0)
Vascular invasion
 Absent 177 84 (47.5) 93 (52.5) 0.045
 Present 28 19 (67.9) 9 (32.1)
Histological differentiation
 Well 11 1 (9.1) 10 (90.9) 0.005
 Moderate/poor 194 102 (52.6) 92 (47.4)
CA199 level(U/ml)
 ≤35 26 11 (9.1) 15 (90.9) 0.627
 >35 105 50 (52.6) 55 (47.4)
 Missing 74

Values in parentheses indicate percentage values. The bold number represents the P-values with significant differences.